Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC "

被引：0
|
作者：
Chen, Ching-Yi [1 ]
Wang, Guo-Sheng [2 ]
Wei, James Cheng-Chung [3 ,4 ,5 ,6 ]
机构：
[1] I Shou Univ, E Da Hosp, Dept Internal Med, Div Chest Med, Kaohsiung, Taiwan
[2] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Pulm & Crit Care Med, Shanghai, Peoples R China
[3] Chung Shan Med Univ Hosp, Dept Allergy Immunol & Rheumatol, Taichung, Taiwan
[4] Chung Shan Med Univ, Inst Med, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan
[5] Chung Shan Med Univ, Dept Nursing, Taichung, Taiwan
[6] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 05期
关键词：
D O I：
10.1016/j.jtho.2024.02.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e6 / e7
页数：2
相关论文
共 50 条
  • [1] Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
    Zhao, Binghao
    Yao, Longping
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05)
  • [2] Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
    Nassar, Amin H.
    Kim, So Yeon
    Aredo, Jacqueline, V
    Feng, Jamie
    Shepherd, Frances
    Xu, Chao
    Kaldas, David
    Gray, Jhanelle E.
    Dilling, Thomas J.
    Neal, Joel W.
    Wakelee, Heather A.
    Liu, Yufei
    Lin, Steven H.
    Abuali, Tariq
    Amini, Arya
    Nie, Yunan
    Patil, Tejas
    Lobachov, Anastasiya
    Bar, Jair
    Fitzgerald, Bailey
    Fujiwara, Yu
    Marron, Thomas U.
    Thummalapalli, Rohit
    Yu, Helena
    Owen, Dwight H.
    Sharp, John
    Farid, Saira
    Rocha, Pedro
    Arriola, Edurne
    'Aiello, Angelica
    Cheng, Haiying
    Whitaker, Ryan
    Parikh, Kaushal
    Ashara, Yash
    Chen, Luxi
    Sankar, Kamya
    Harris, Jeremy P.
    Nagasaka, Misako
    Ayanambakkam, Adanma
    Velazquez, Ana I.
    Ragavan, Meera
    Lin, Jessica J.
    Piotrowska, Zo fia
    Wilgucki, Molly
    Reuss, Joshua
    Luders, Heike
    Grohe, Christian
    Espinar, Javier Baena
    Feiner, Ella
    Punekar, Salman R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (06) : 928 - 940
  • [3] EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
    Nassar, Amin
    Adib, Elio
    Feng, Jamie
    Aredo, Jacqueline V.
    Parikh, Kaushal
    Harris, Jeremy Phillip
    Manana, Ana I. Velazquez
    Ragavan, Meera Vimala
    Lin, Jessica Jiyeong
    Piotrowska, Zofia
    Fitzgerald, Bailey Gleason
    Grohe, Christian
    Sankar, Kamya
    Neal, Joel W.
    Wakelee, Heather A.
    Shepherd, Frances A.
    Herbst, Roy S.
    Naqash, Abdul Rafeh
    Goldberg, Sarah B.
    Kim, So Yeon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 1999 - 2001
  • [5] Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC
    V. Aredo, Jacqueline
    Hellyer, Jessica A.
    Neal, Joel W.
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 1994 - 1998
  • [6] To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC
    Bauman, Jessica
    Borghaei, Hossein
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 894 - 896
  • [7] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [9] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [10] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
12345